A proposed staging system and stage-specific interventions for familial adenomatous polyposis

详细信息    查看全文

• 作者：Patrick M. Lynch ; MD¹ ; ; Jeffrey S. Morris ; PhD² ; Sijin Wen ; PhD³ ; Shailesh M. Advani ; MD ; MPH¹ ; William Ross ; MD¹ ; George J. Chang ; MD ; MS⁴ ; Miguel Rodriguez-Bigas ; MD ; FACS ; FASCRS⁴ ; Gottumukkala S. Raju ; MD ; FASGE¹ ; Luigi Ricciardiello ; MD⁵ ; Takeo Iwama ; MD⁶ ; Benedito M. Rossi ; MD ; PhD⁷ ; Maria Pellise ; MD ; PhD⁸ ; Elena Stoffel ; MD ; MPH⁹ ; Paul E. Wise ; MD¹⁰ ; Lucio Bertario ; MD¹¹ ; Brian Saunders ; MD ; PRCP¹² ; Randall Burt ; MD¹³ ; Andrea Belluzzi ; MD¹⁴ ; Dennis Ahnen ; MD¹⁵ ; Nagahide Matsubara ; MD¹⁶ ; Steffen Bü ; low ; MD ; DMSc¹⁷ ; Niels Jespersen ; MD¹⁷ ; Susan K. Clark ; MD ; FRCS¹⁸ ; Steven H. Erdman ; MD¹⁹ ; Arnold J. Markowitz ; MD²⁰ ; Inge Bernstein ; MD ; PhD ; MHM²¹ ; Niels De Haas ; MD²¹ ; Sapna Syngal ; MD ; MPH²² ; Gabriela Moeslein ; MD²³
• 关键词：FAP ; familial adenomatous polyposis ; FDA ; Food and Drug Administration ; InSiGHT ; International Society for Gastrointestinal Hereditary Tumors ; ICC ; intraclass correlation coefficient ; IPSS ; InSiGHT polyposis staging system
• 刊名：Gastrointestinal Endoscopy
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：84
• 期：1
• 页码：115-125.e4
• 全文大小：1251 K

文摘

It is not possible to accurately count adenomas in many patients with familial adenomatous polyposis (FAP). Nevertheless, polyp counts are critical in evaluating each patient’s response to interventions. However, the U.S. Food and Drug Administration no longer recognizes the decrease in polyp burden as a sufficient chemoprevention trial treatment endpoint requiring a measure of “clinical benefit.” To develop endpoints for future industry-sponsored chemopreventive trials, the International Society for Gastrointestinal Hereditary Tumors (InSIGHT) developed an FAP staging and intervention classification scheme for lower-GI tract polyposis.

Methods

Twenty-four colonoscopy or sigmoidoscopy videos were reviewed by 26 clinicians familiar with diagnosis and treatment of FAP. The reviewers independently assigned a stage to a case by using the proposed system and chose a stage-specific intervention for each case. Our endpoint was the degree of concordance among reviewers staging and intervention assessments.

Results

The staging and intervention ratings of the 26 reviewers were highly concordant (ρ = 0.710; 95% credible interval, 0.651-0.759). Sixty-two percent of reviewers agreed on the FAP stage, and 90% of scores were within ±1 stage of the mode. Sixty percent of reviewers agreed on the intervention, and 86% chose an intervention within ±1 level of the mode.

Conclusions

The proposed FAP colon polyposis staging system and stage-specific intervention are based on a high degree of agreement on the part of experts in the review of individual cases of polyposis. Therefore, reliable and clinically relevant means for measuring trial outcomes can be developed. Outlier cases showing wide scatter in stage assignment call for individualized attention and may be inappropriate for enrollment in clinical trials for this reason.